Sysmex Reveals OncoBEAM IVD Test in France

German company Sysmex Inostics has unveiled its first RAS biomarker testing site at the Biopathology department of the Institut de Cancérologie de Lorraine in France.

The site will utilize the company’s OncoBEAM IVD test, which was jointly developed by Sysmex and Merck.

The blood-based test is designed to evaluate RAS status to facilitate therapy planning for patients with RAS wild type metastatic colorectal cancer. — Anisa Jibrell